London, United Kingdom and Hyderabad, India: February 9, 2022 – A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets.
Machine learning and artificial intelligence are reshaping discovery and optimization of drug candidates. This synergistic new partnership between Excelra’s GOSTAR® and X-Chem’s RosalindAI will enable unique and powerful tools to predict small molecules, chemical, biological, and physical properties, accelerating time and resource-intensive stages of drug discovery from hit identification to preclinical candidate selection.
“This is a perfect match between two of the best solutions for some hard challenges in drug discovery,” said Norman Azoulay, Director, Scientific Products. “We’re convinced this partnership will immediately help drug developers fuel their pipelines better.”
GOSTAR®’s proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem’s RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets. The results confirmed that RosalindAI’s proprietary models are designed specifically to address challenges in chemical datasets, and when trained on the larger, more diverse GOSTAR® data, yielded models twice as better than models trained on other datasets.
X-Chem SVP Noor Shaker says: “AI is revolutionizing drug discovery in ways never thought possible before, and RosalindAI is leading the way with AI tools that are accurate, scalable, and robust, enabling a transformation in preclinical drug discovery. Our collaboration with Excelra will enable us to leverage GOSTAR® data and enable AI in ways never possible before.”
GOSTAR® provides a unique 360⁰ view of over 8 million small molecules. The content in GOSTAR® is meticulously curated with a proprietary QMS-ISO certified process. It captures the most up-to-date view of the chemical space with information on chemical structures and their biological properties, including binding, in-vitro, in-vivo, ADME, Tox, and physicochemical properties.
X-Chem’s RosalindAI is a leading AI platform for preclinical drug discovery. It provides a seamless interface to build best-in-class AI models for chemical design and optimization. It has also been successfully applied to the design of a novel chemotype for challenging targets and for the accurate prediction of chemical activities and properties.
About Excelra and GOSTAR®:
Excelra’s data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how & technologies to accelerate drug discovery and development with reliable and result-oriented insights. Excelra’s GOSTAR® is an application available for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.
For more information about GOSTAR®, visit https://www.gostardb.com/
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. With industry-leading expertise in medicinal chemistry, custom synthesis and scale-up process chemistry and a proprietary AI platform to support and accelerate all aspects of drug discovery, X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate.